156 related articles for article (PubMed ID: 20151855)
1. The somatostatin receptor subtype 5 in neuroendocrine tumours.
van der Hoek J; Lamberts SW; Hofland LJ
Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
3. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
4. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
8. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
9. Pituitary tumours: the sst/D2 receptors as molecular targets.
Hofland LJ; Feelders RA; de Herder WW; Lamberts SW
Mol Cell Endocrinol; 2010 Sep; 326(1-2):89-98. PubMed ID: 20438803
[TBL] [Abstract][Full Text] [Related]
10. New SRIF analogs in the control of human pituitary adenomas: perspectives.
Jaquet P; Saveanu A; Barlier A
J Endocrinol Invest; 2005; 28(5 Suppl):14-8. PubMed ID: 16114269
[TBL] [Abstract][Full Text] [Related]
11. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.
Veenstra MJ; de Herder WW; Feelders RA; Hofland LJ
Expert Opin Ther Targets; 2013 Nov; 17(11):1329-43. PubMed ID: 23991721
[TBL] [Abstract][Full Text] [Related]
12. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
13. Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells.
Hofland LJ; Lamberts SW; Feelders RA
Neuroendocrinology; 2010; 92 Suppl 1():11-6. PubMed ID: 20829612
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
[TBL] [Abstract][Full Text] [Related]
15. Future aspects of somatostatin-receptor-mediated therapy.
Oberg K
Neuroendocrinology; 2004; 80 Suppl 1():57-61. PubMed ID: 15477719
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
17. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
18. Function and expression of somatostatin receptors of the endocrine pancreas.
Strowski MZ; Blake AD
Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
[TBL] [Abstract][Full Text] [Related]
19. Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view.
Prasad V; Fetscher S; Baum RP
J Pharm Pharm Sci; 2007; 10(2):321s-337s. PubMed ID: 17718935
[No Abstract] [Full Text] [Related]
20. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]